Scarica l'app Stockscreener
12.93
2.54%
0.32
CorMedix Inc Borsa (CRMD) Ultime notizie
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT - MSN
CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study - TipRanks
Why CorMedix (CRMD) Might be Well Poised for a Surge - sharewise.com
Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention - TipRanks
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position - simplywall.st
CorMedix (CRMD.O) Surges 8% — Is It a Technical Trigger or a Broader Sector Play? - AInvest
CorMedix Raises $150M in Convertible Notes Offering - AInvest
Undervalued Healthcare Stocks to Buy: Eli Lilly, CorMedix, and Johnson & Johnson - AInvest
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - ca.finance.yahoo.com
Will CorMedix Inc. benefit from AI trendsJuly 2025 Chart Watch & Daily Technical Forecast Reports - mustnews.co.kr
Momentum Screeners Rank CorMedix Inc. in Top 5 TodayAI Screening for Swing Trade Picks Finds Momentum - sundaytimes.kr
CorMedix Inc. Just Beat EPS By 50%: Here's What Analysts Think Will Happen Next - 富途牛牛
CorMedix Completes $150M Convertible Notes Offering - TipRanks
CorMedix completes $150 million convertible notes offering on Nasdaq By Investing.com - Investing.com Nigeria
CorMedix completes $150 million convertible notes offering on Nasdaq - Investing.com
Unpacking CorMedix’s 14.2% Intraday Surge: What’s Driving the Move? - AInvest
CorMedix (CRMD.O) Surges 9.7% Intraday—No Fundamentals, So What's Driving It? - AInvest
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook - Investing.com
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Zacks Investment Research
CorMedix Inc. (NASDAQ:CRMD) Q2 2025 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Earnings Call Highlights Strategic Growth - TipRanks
Both Individual Investors Who Control a Good Portion of CorMedix Inc. (NASDAQ:CRMD) Along With Institutions Must Be Dismayed After Last Week's 16% Decrease - 富途牛牛
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
CorMedix Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - MSN
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
HC Wainwright Maintains Buy Rating on Cormedix, Adjusts Price Target to $17.00 - AInvest
Unraveling the Drop in CorMedix (CRMD.O): A Technical and Market Flow Deep Dive - AInvest
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... By GuruFocus - Investing.com Canada
CorMedix signs agreement to acquire Melinta for $300m - Yahoo Finance
CorMedix: Q2 Earnings Snapshot - Greenwich Time
CorMedix Inc. Reports Strong Q2 2025 Results - TipRanks
Transcript : CorMedix Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition - TipRanks
CorMedix (CRMD.O) Suffers Sharp Intraday Drop: What’s the Story Behind? - AInvest
CRMD Faces Major Legal Battle - StocksToTrade
CorMedix Surpasses Expectations with Q2 Earnings Surge - AInvest
CorMedix Forecasts FY25 Pro Forma Revenue of $305M-$335M - AInvest
M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal - TipRanks
CorMedix buys Melinta Therapeutics for $300M - ROI-NJ
Cormedix Inc. shares fall 11.38% intraday after announcing $260M acquisition of Melinta Therapeutics, raising dilution and financing concerns. - AInvest
CorMedix To Acquire Melinta Therapeutics In $300 Mln Deal To Expand Infectious Disease Portfolio - Nasdaq
CorMedix to Buy Melinta Therapeutics for $300 Million - The Wall Street Journal
CorMedix to acquire Melinta Therapeutics for $300M - TipRanks
CorMedix Inc. SEC 10-Q Report - TradingView
CorMedix Announces Merger Agreement with Melinta Therapeutics - TipRanks
CorMedix To Acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence In Acute Care Settings - TradingView
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):